阿帕提尼布加上ifosfamide和etoposide与ifosfamide和etoposide在患有晚期骨髓瘤的患者中 (OAIE/PKUPH-sarcoma 11):一个随机的II期研究
1Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Nature communications
|November 25, 2025
概括
将阿帕蒂尼布添加到化疗中,改善了复发性或耐药性骨髓瘤患者的无进展生存期. 这种组合疗法为这种具有挑战性的癌症提供了潜在的新治疗选择. 需要进一步的III期试验来确认.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 复发性或耐火性骨髓瘤在标准化疗中预后不佳.
- 对于在初始化疗后进展的患者,有效的治疗选择有限.
研究的目的:
- 在患有复发性或耐火性骨髓瘤的患者中,比较阿帕蒂尼布加 ifosfamide/etoposide (IE) 与单独IE的疗效.
- 评估阿帕蒂尼布对该患者群体无进展生存期 (PFS) 的影响.
主要方法:
- 一个多中心,随机的II期试验 (NCT05277480) 招募了81名患者.
- 患者被随机分为2:1接受阿帕蒂尼布加IE或单独IE.
- 主要终点是无进展生存期 (PFS).
主要成果:
- 平均PFS为阿帕蒂尼布加IE的5.5个月,与单独IE的3.4个月相比 (危险比率:0.60;P=0.0402).
- 阿帕蒂尼布和IE的组合表明PFS在统计学上有显著的改善.
- 该试验达到其主要终点,表明阿帕蒂尼布的潜在益处.
结论:
- 阿帕蒂尼布加上ifosfamide/etoposide可以改善复发性或耐火性骨髓瘤的PFS.
- 这些探索性发现需要在更大的III期临床试验中得到证实.
- 阿帕提尼布代表了晚期骨髓瘤化疗方案的有前途的补充.
相关概念视频
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


